Clinical trials: Carbapenems
Antimicrobial Drug Resistance, Antibiotic Resistant Infection
Dynamics of Colonization and Infection by Multidrug-Resistant Pathogens in Immunocompromised and Critically Ill Patients
The goal of this observational study is to investigate how bacterial populations from the intestine and mouth of patients change during the hospitalization period and evaluate if some populations of specific bacteria increase or…
- Conditions
- Antimicrobial Drug Resistance, Antibiotic Resistant Infection, Clostridium Difficile, Carbapenem-Resistant Enterobacteriaceae Infection
- Trial name
- DYNAMITE (NCT06258551)
- Where
- 2 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- The Methodist Hospital Research Institute
ECMO, Carbapenem-Resistant Enterobacteriaceae Infection
Precise Treatment of Ceftazidime-Avibactam in Patients With CRO Infections Under the Guidance of TDM and PPK Model
The goal of this study is to evaluate the efficacy and safety of ceftazidime-avibactam(CAZ-AVI) in the treatment of critically ill patients with carbapenem-resistant organisms(CRO) infections (including dialysis patients and…
- Trial name
- NCT06210542
- Testing
- ceftazidime avibactam
- Volunteers
- 50 people
- Sponsor
- Sichuan Provincial People's Hospital
Carbapenem-resistant Enterobacteriaceae
The Population Pharmacokinetics Study of Tigecycline and Pharmacokinetics- Pharmacodynamics Index in Patients With Carbapenem Resistant Enterobacteriaceae Bloodstream Infection
Carbapenem-resistant Enterobacteriaceae (CRE) are an urgent global public health problem. Patients who were infected caused by CRE bloodstream infection were high mortality up to 40%.
- Trial name
- NCT06049771
- Testing
- Collect blood sample
- Where
- Thailand
- Volunteers
- 72 people
- Sponsor
- Phramongkutklao College of Medicine and Hospital
Carbapenem Resistant Bacterial Infection, Hemophagocytic Lymphohistiocytoses
Efficacy and Safety of Carrimycin Tablets in HLH Patients With Carbapenem-resistant Infections
This study aimed to investigate the efficacy and safety of Carrimycin tablets in hemophagocytic lymphohistiocytosis patients with Carbapenem-resistant infections.
- Trial name
- NCT05988177
- Testing
- Carrimycin tablets
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Friendship Hospital
Carbapenem Resistant Klebsiella Pneumoniae
Dose Optimization by Pharmacokinetic/Pharmacodynamic of Antibiotics to Improve Clinical Outcome of Carbapenem Resistant Klebsiella Pneumoniae Bloodstream Infections in Critically Ill Patients at Phramongkutklao Hospital
The patients who infected with Carbapenem resistant Klebsiella pneumoniae were high mortality rate. Appropriate antibiotics therapy adjusted by Pharmacokinetic/Pharmacodynamic plays an important role in determining outcomes in…
- Trial name
- NCT05862402
- Testing
- Dose-adjustment by PKPD
- Where
- Thailand
- Volunteers
- 76 people
- Sponsor
- Phramongkutklao College of Medicine and Hospital
Carbapenem-Resistant Enterobacteriaceae Infection
Drug Resistance Mechanism of Enterobacteriaceae and Its Strategies
The first aim of this study is to explore the drug resistance mechanism of Enterobacteriaceae bacteria and to evaluate the treatment effect of ceftazidime-avibactam (CAZ-AVI) in combination with aztreonam (ATM) against…
- Trial name
- NCT05850871
- Testing
- CAZ/AVI plus Aztreonam, Conventional treatment
- Where
- China
- Volunteers
- 427 people
- Sponsor
- Qianfoshan Hospital
Febrile Neutropenia, Pharmacokinetics
Population Pharmacokinetics/Pharmacodynamics of Carbapenems in Febrile Neutropenia Patients
1. Evaluating the differences in the efficacy and safety of meropenem optimal dosing regimen predicted by the PPK/PD model combined with MAPB method for patients with malignant hematological myelopathy accompanied by fever, as…
- Conditions
- Febrile Neutropenia, Pharmacokinetics, Pharmacodynamic, Carbapenems
- Trial name
- NCT05665478
- Testing
- Dose prediction using population pharmacokinetic models
- Volunteers
- 100 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Carbapenem-Resistant Enterobacteriaceae Infection
Fecal Microbiota Transplantation for Carbapenem-resistant Enterobacteriaceae
2:1, open-label, single center, randomized controlled trial comparing FMT vs. no intervention for CRE carriers,
- Trial name
- NCT04146337
- Testing
- FMT
- Where
- Israel
- Volunteers
- 3 people
- Sponsor
- Rambam Health Care Campus
Staphylococcus Aureus, Carbapenem Resistant Gram Negative Bacteria
Targeted Gown and Glove Intervention in Nursing Homes
This project will assess the feasibility of a cluster-randomized trial with crossover of our intervention, targeted gown and glove use, among high-risk residents of community nursing homes to prevent Staphylococcus aureus and…
- Trial name
- TAGG (NCT04200508)
- Testing
- Targeted gown and gloves use
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Maryland, Baltimore
Carbapenem-Resistant Enterobacteriaceae Infection
Fecal Microbiota Transplantation for Carbapenem Resistant Enterobacteriaceae
Open-label, single center, prospective interventional non-comparative study for CRE carriers.
- Trial name
- NCT04790565
- Testing
- FMT
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Rambam Health Care Campus
Carbapenem-Resistant Enterobacteriaceae Infection, Bloodstream Infection
Best Available Therapy With or Without Meropenem for Bloodstream Infections by Enterobacterales With High Level of Resistance to Carbapenems
Enterobacterales resistant to carbapenem are cause of severe concern in hospital-acquired infections since therapeutic options are limited.
- Trial name
- ABOVE (NCT04876430)
- Testing
- Meropenem
- Where
- 2 sites in Brazil
- Volunteers
- 13 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Hematological Diseases, Carbapenem-resistant Enterobacteriaceae
Carbapenem-resistant Organisms (CRO) Screening From Rectal Swabs in Patients With Hematological Diseases in China
Carbapenem-resistant Organisms (CRO) include Carbapenem-resistant Enterobacteriaceae (CRE), Carbapenem-resistant Pseudomonas aeruginosa (CRPA) and Carbapenem-resistant Acinetobacter baumannii (CRAB).
- Conditions
- Hematological Diseases, Carbapenem-resistant Enterobacteriaceae, Carbapenem-resistant Pseudomonas Aeruginosa, Carbapenem-resistant Acinetobacter Baumannii
- Trial name
- CROSS (NCT05002582)
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- Sir Run Run Shaw Hospital
Carbapenem-Resistant Enterobacteriaceae Infection
Impact of Ceftazidime / Avibactam Treatment vs Better Available Therapy on Mortality of Patients With Infections Caused by Carbapenem-resistant Enterobacteria
Patients with infections caused by carbapenem-resistant enterobacteria treated with CAZ-AVI versus patients treated with BAT are compared. The BAT group includes fosfomycin, tigecycline, gentamicin, meropenem and colistin.
- Trial name
- CAVICOR (NCT04167228)
- Testing
- Ceftazidime-Avibactam, Best Available Therapy
- Where
- 17 sites in Spain
- Volunteers
- 348 people
- Sponsor
- Maimónides Biomedical Research Institute of Córdoba
Carbapenem-Resistant Enterobacteriaceae
Clinical Validation of the Molecular-Based GenePOC Carba Assay for the Detection and Differentiation of Carbapenemase Genes in Rectal Swab Samples.
The primary purpose of this clinical investigation is to establish the performance of the GenePOC Carba assay on the revogene. This will be achieved by comparing the test to a conventional method for detection of Carbapenemase…
- Trial name
- NCT03680898
- Testing
- Rectal swab collection
- Where
- 3 sites in United States, Canada
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Meridian Bioscience, Inc.
Carbapenem Resistant Bacteria Infection
European Prospective Cohort Study on Enterobacteriaceae Showing Resistance to Carbapenems
Among antibiotic-resistant organisms, the Gram-negative bacteria are now the most important challenge because of the rapid worldwide spread of mechanisms conferring resistance to multiple drugs.
- Trial name
- EURECA (NCT02709408)
- Where
- 50 sites in Albania, Bulgaria and 9 more
- Volunteers
- 2,515 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Carbapenem-Resistant Enterobacteriaceae Infection
Oral Capsule Faecal Microbiota Transplantation for CPE Decolonization
Double-blinded, randomised controlled trial to evaluate the clinical efficacy of a single dose of oral capsule-administered faecal microbiota transplantation (FMT) for carbapenemase-producing Enterobacteriaceae (CPE) intestinal…
- Trial name
- NCT04746222
- Testing
- Oral capsule faecal microbiota transplantation
- Volunteers
- 108 people
- Sponsor
- Tan Tock Seng Hospital
Vancomycin-Resistant Enterococcus, Extended-Spectrum Beta Lactamase-Producing Enterobacteriaceae, or Carbapenem-Resistant Enterobacteriaceae Colonized Subjects
VITORA: Clinical Study to Evaluate the Effect of KB109 on the Gut Microbiome in Subjects Whose Gastrointestinal Tracts Are Colonized With Multiple Drug-resistant Organisms
This randomized, open-label, clinical study aims to explore the safety and tolerability of KB109, a novel glycan, versus an observational control group on the gut microbiome in subjects whose gastrointestinal tracts are colonized…
- Trial name
- VITORA (NCT03944369)
- Testing
- KB109, No intervention
- Where
- 8 sites in United States
- Volunteers
- 3 people
- Sponsor
- Kaleido Biosciences
Drug Resistance, Carbapenem-Resistant Enterobacteriaceae Infection
Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae
The purpose of this study is to evaluate the treatment outcomes in patients with CRE infections.
- Conditions
- Drug Resistance, Carbapenem-Resistant Enterobacteriaceae Infection, Sepsis, Septic Shock
- Trial name
- NCT04516395
- Testing
- Combined antibiotic regimens, Standard antibiotic regimens
- Where
- Thailand
- Volunteers
- 102 people
- Sponsor
- Phramongkutklao College of Medicine and Hospital
Sepsis, Septic Shock
Clinical Outcome Study of High-dose Meropenem in Sepsis and Septic Shock Patients
Sepsis and septic shock patients are considered to have a high risk of complications and death. Appropriate antimicrobial therapy plays an important role in determining outcomes in septic patients.
- Conditions
- Sepsis, Septic Shock, Critical Illness, Carbapenem
- Trial name
- NCT03344627
- Testing
- Meropenem standard dose, Meropenem high dose
- Where
- Thailand
- Volunteers
- 76 people
- Sponsor
- Mahidol University
ESBL Producing E.Coli, ESBL Producing K.Pneumoniae
Epidemiology of Resistant Microbial Strains Among Different Groups of People (Healthy, Infected and Exposed to Animals)
This study investigates carriage rate and risk factors for acquiring multiresistant bacteria (ESBL producing E.coli and K.pneumoniae, carbapenem-resistant and multidrug resistant P.aeruginosa, MRSA and VRE) in hospitalised…
- Conditions
- ESBL Producing E.Coli, ESBL Producing K.Pneumoniae, Multidrug Resistant P.Aeruginosa, Carbapenem Resistant P.Aeruginosa
- Trial name
- ABRESIST (NCT03343119)
- Volunteers
- 708 people, healthy volunteers welcome
- Sponsor
- University of Tartu